Psyence BioMed has begun dosing the first patient in its Phase IIb clinical trial of NPX-5, a nature-derived psilocybin treatment for Adjustment Disorder in cancer patients receiving palliative care. This trial, conducted across five Australian sites, aims to evaluate the safety, efficacy, and durability of a 25mg dose of psilocybin to address psychological distress in seriously ill patients. The data generated will guide future development and regulatory strategies as Psyence BioMed advances its vertically integrated platform for psychedelic therapeutics. This marks a significant step in developing new mental health treatments for unmet needs in palliative care.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Frasers Group PLC has withheld financial guidance for the upcoming year due to uncertainty around its takeover bids for Hugo Boss and Accent Group. The retailer's full-year adjusted profit before tax fell 4% to £538 million, impacted by asset impairm...
Ethereum rose 3.17% to $1,923.53, outperforming Bitcoin's modest 0.18% gain to $64,588.87, signaling an early rotation toward large-cap altcoins. Despite this, overall market activity slowed, with declines in DeFi, stablecoin, and derivatives trading...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
